Drug
Asunaprevir clinical trials
Also written BMS-650032.
- studies test it
- 29
- open now
- 0
- in phase 3
- 9
- first study started
- 2008
How studies write it
Studies that test it under each name
Name
Brand
Development codes
Combined with it in one product
Studies by the year they started
29 studies that test it; most in 2014 (11)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 11 |
| 2015 | 1 |
| 2016 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 9
- Phase 3
- 9
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 22 · Other 7
Bristol-Myers Squibb (22) · ANRS, Emerging Infectious Diseases (2) · Kaohsiung Medical University Chung-Ho Memorial Hospital (1) · Myeong Jun Song (1) · National Institutes of Health Clinical Center (CC) (1) · Timothy Morgan, MD (1) · Foundation for Liver Research (1)
Often tested with
Tested in the same studies.
Daclatasvir (23) · Beclabuvir (9) · Ribavirin (8) · Peginterferon alfa-2a (3) · Interferon alpha-2 (1) · Sofosbuvir (1) · Peginterferon lambda-1a (1) · Rosuvastatin (1)
Studies
Open first, then newest update. How each study uses asunaprevir is read from its arms, and is right about nine times in ten.
Testing it · 29
- Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)CompletedPhase 2ANRS, Emerging Infectious DiseasesNCT02107365Written as Asunaprevir
- A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1CompletedPhase 3Bristol-Myers SquibbNCT02170727Written as DCV/ASV/BMS-791325
- Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude DualCompletedPhase 3Bristol-Myers SquibbNCT01995266Written as Asunaprevir
- Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)CompletedPhase 2Bristol-Myers SquibbNCT02175966Written as DCV/ASV/BMS-791325
- Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAVCompletedPhase 3Kaohsiung Medical University Chung-Ho Memorial HospitalNCT03004625Written as asunaprevir
- The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal FailureCompletedPhase 4Myeong Jun SongNCT02580474Written as Daclatasvir plus Asunaprevir
- Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCVCompletedPhase 2National Institutes of Health Clinical Center (CC)NCT02124044Written as Asunaprevir and Daclatasvir
- A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b InfectionCompletedPhase 3Bristol-Myers SquibbNCT02496078Written as Asunaprevir
- Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus TrialsCompletedPhase 2Bristol-Myers SquibbNCT01428063Written as Asunaprevir
- Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C VirusCompletedNot applicableTimothy Morgan, MDNCT02098616Written as DCV/ASV/BMS-791325
- UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic SubjectsCompletedPhase 3Bristol-Myers SquibbNCT01979939Written as DCV/ASV/BMS-791325
- Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV PatientsCompletedPhase 3Foundation for Liver ResearchNCT02282709Written as asunaprevir
- A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) PatientsCompletedPhase 3Bristol-Myers SquibbNCT01497834Written as BMS-650032 (Asunaprevir)
- An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) SubjectCompletedPhase 2Bristol-Myers SquibbNCT01051414Written as BMS-650032
- Study of BMS-650032 With Peginterferon Alfa-2a Plus RibavirinCompletedPhase 2Bristol-Myers SquibbNCT01030432Written as BMS-650032
- Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCompletedPhase 2Bristol-Myers SquibbNCT01309932Written as BMS-650032 (NS3 Protease Inhibitor)
- A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV SubjectsCompletedPhase 3Bristol-Myers SquibbNCT01718145Written as Asunaprevir
- Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)CompletedPhase 3Bristol-Myers SquibbNCT01573351Written as Asunaprevir
- A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and AsunaprevirCompletedPhase 1Bristol-Myers SquibbNCT02323594Written as Asunaprevir
- Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325CompletedPhase 1Bristol-Myers SquibbNCT02095860Written as DCV 3DAA FDC
See all 29 studies that test asunaprevir →
Given in every arm · 6 — asunaprevir is usual care beside what is tested
- Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available MedicationsCompletedPhase 2Bristol-Myers SquibbNCT01455090Written as BMS-650032
- Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of CareCompletedPhase 2Bristol-Myers SquibbNCT01012895Written as BMS-650032
- UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated CirrhosisCompletedPhase 3Bristol-Myers SquibbNCT01973049Written as Asunaprevir
- Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)CompletedPhase 3Bristol-Myers SquibbNCT01581203Written as Asunaprevir (ASV)
- Study of Drug Combination on Pharmacokinetics in Healthy VolunteersCompletedPhase 1Bristol-Myers SquibbNCT02175602Written as DCV 3DAA FDC
- Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT02045966Written as DCV 3DAA FDC
As the comparator · 1 — what is tested is compared with asunaprevir
Codes
What other systems call asunaprevir · ClinicalTrials.gg INT006053
- MeSH (NLM) C571889asunaprevirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) S9X0KRJ00SASUNAPREVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1652103Confirmed FDA, Wikidata
- Wikidata Q4811881asunaprevirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C114982AsunaprevirOne source FDA
- DrugBank DB11586One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C571889 | asunaprevir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | S9X0KRJ00S | ASUNAPREVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1652103 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4811881 | asunaprevir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C114982 | Asunaprevir | One source FDA |
| DrugBank | DB11586 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.